Skip to main content

Table 3 Exposure to treatment for patients treated with either mFOLFOX-6 plus cetuximab (FOLFOX + Cmab) or XELOX plus cetuximab (XELOX + Cmab)

From: Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study

  All (n = 62) FOLFOX + Cmab (n = 37) XELOX + Cmab (n = 25)
No. treatment cycles    
 Median 10 (5.5–17.5) 10 (5–19) 9.5 (6–14)
Cetuximab treatment    
 Cumulative dose (mg/m2) 6480 (2187–12 480) 6750 (3580–14 634) 6397 (4302–11 198)
 DI (mg/m2 per week) 216 (189–247) 223 (189–233) 237 (179–261)
 No. with relative DI >75 % 52 28 24
Oxaliplatin    
 Cumulative dose (mg/m2) 992 (600–1812) 987 (505–2021) 1008 (661–1597)
 DI (mg/m2 per week) 31.4 (24–39) 30 (28–35) 39 (29–42)
 No. with relative DI >75 % 37 20 17
Bolus 5-FU    
 Cumulative dose (mg/m2)   4392 (1795–9928)  
 DI (mg/m2 per week)   135 (120–175)  
 No. with relative DI >75 %   21  
5-FU Infusion    
 Cumulative dose (mg/m2)   28414 (14750–60644)  
 DI (mg/m2 per week)   890 (803–1062)  
 No. with relative DI >75 %   21  
Capecitabine    
 Cumulative dose (mg/m2)    23700 (14250–38925)
 DI (mg/m2 per week)    878 (666–978)
 No. with relative DI >75 %    16
  1. Numbers in parenthesis show the interquartile range
  2. DI dose intensity, 5-FU 5-fluorouraci